By: Bec Roldan, PhD From: breastcancer.org For more than 15 years, healthcare workers in the U.S. have been calling attention to the importance of taking early steps to improve the quality of life in people diagnosed with advanced cancer. Despite these efforts, a recent study found that many people over 65 with advanced cancer aren’t receiving supportive care in the …
Powerful new therapy doubles progression-free survival in advanced breast cancer
From: cr.ac.uk A powerful three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown. The INAVO120 study, led by Professor Nicholas Turner of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, demonstrates the potential of the …
Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer
By: Kyle Doherty From: onclive.com Frontline treatment with ribociclib (Kisqali) in combination with endocrine therapy displayed a significant progression-free survival (PFS) benefit with superior tolerability vs combination chemotherapy in patients with clinically aggressive hormone receptor–positive, HER2-negative advanced breast cancer, according to findings from the phase 2 RIGHT Choice trial (NCT03839823) published in the Journal of Clinical Oncology. At a median …
New understanding of devastating type of breast cancer spread could lead to better treatments
From: icr.ac.uk A new study has increased the understanding of an increasingly common complication of advanced breast cancer. Using a novel approach, researchers have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing effective treatments for people whose disease progresses in this way. The study revealed for the first time that breast …
Small Proportion of Advanced Breast Cancers Due to Biennial Versus Annual Mammogram
By: Elana Gotkine From: healthday.com BMI population attributable risk proportions highest for premenopausal and postmenopausal Blacks, postmenopausal Hispanic/Latinx Among routinely screened women, only a small proportion of advanced breast cancers is attributed to biennial versus annual screening, according to a study published online Dec. 7 in JAMA Oncology. Karla Kerlikowske, M.D., from the University of California in San Francisco, and …
Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer
From: targetedonc.com In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer. CASE SUMMARY A 62-year-old woman presented with a 6 cm right breast mass, which has been slowly growing for 1 year with palpable axillary nodes. Her liver function test …
PET/CT-FDG vs Conventional Staging in Locally Advanced Breast Cancer
By: Matthew Stenger From: ascopost.com In a Canadian study reported in the Journal of Clinical Oncology, Dayes et al found that positron-emission tomography/computed tomography–fluorodeoxyglucose (PET/CT-FDG) improved the detection of distant metastasis vs conventional staging in patients with locally advanced breast cancer. It also reduced the use of curative-intent combined-modality therapy. Study Details In the open-label trial, 369 patients with invasive …
Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer
By: Kristi Rosa From: oncnursingnews.com Patients with hormone receptor–positive advanced breast cancer achieved superior progression-free survival (PFS) with capivasertib plus fulvestrant (Faslodex) than with fulvestrant alone. PFS benefit was also reported those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.1 Data from an exploratory analysis of PFS in key subgroups from the …
MONALEESA-2 Subgroup Analysis Highlights Survival Benefit With Ribociclib/Letrozole in HR+ Breast Cancer
By: Courtney Flaherty From: onclive.com The frontline combination of ribociclib (Kisqali) and letrozole significantly prolonged overall survival (OS) over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial (NCT01958021).1 Findings …
New interactive tool helps to calculate risk of developing advanced breast cancer
Source: University of California, San Francisco (UCSF) From: news-medical.net Breast cancer is now the leading cause of global cancer incidence among women but determining who will develop breast cancer is still a challenge for the medical community. A new tool, developed by researchers from UCSF and several other medical institutions, helps to calculate risk for those who may develop advanced …